Skip to Content


In the US, Cyclophosphamide (cyclophosphamide systemic) is a member of the drug class alkylating agents and is used to treat Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Bladder Cancer, Brain Tumor, Breast Cancer, Bullous Pemphigoid, Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Cogan's Syndrome, Dermatomyositis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ewing's Sarcoma, Granulomatosis with Polyangiitis, Histiocytosis, Hodgkin's Lymphoma, IgA Nephropathy, Mantle Cell Lymphoma, Multiple Myeloma, Multiple Sclerosis, Mycosis Fungoides, Nephrotic Syndrome, Neuroblastoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer, Organ Transplant - Rejection Prophylaxis, Osteosarcoma, Ovarian Cancer, Pemphigoid, Pemphigus, Prostate Cancer, Rheumatoid Arthritis, Scleroderma, Small Cell Lung Cancer, Systemic Lupus Erythematosus, Systemic Sclerosis, Testicular Cancer and Wilms' Tumor.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Disease-modifying antirheumatic drug, DMARD

Cytostatic alkylating agent

Chemical Name

2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroetyl)tetrahydro-, 2-oxide

Foreign Names

  • Cyclophosphamidum (Latin)
  • Cyclophosphamid (German)
  • Cyclophosphamide (French)
  • Ciclofosfamida (Spanish)

Generic Names

  • Cyclophosphamide (OS: DCF, BAN)
  • B 518 (IS)
  • CYP (IS)
  • Ledoxina (IS)
  • NSC 26271 (IS)
  • Cyclophosphamide (PH: Ph. Eur. 8, Ph. Int. 4, USP 38)
  • Cyclophosphamide Hydrate (OS: JAN)
  • Ciclofosfamide (PH: Ph. Eur. 8)
  • Cyclophosphamid (PH: Ph. Eur. 8)
  • Cyclophosphamide (PH: BP 2016, USP 38)
  • Cyclophosphamide Hydrate (PH: JP XVI)
  • Cyclophosphamidum (PH: Ph. Eur. 8, Ph. Int. 4)

Brand Names


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.